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Confocal Raman microscopy, a non-invasive, label-free, and high spatial resolution imaging
technique is employed to trace the anticancer drug paclitaxel in living Michigan Cancer Foundation-
7 (MCF-7) cells. The Raman images were treated by K-mean cluster analysis to detect the drug in
cells. Distribution of paclitaxel in cells is verified by calculating the correlation coefficient between
the reference spectrum of the drug and the whole Raman image spectra. A time dependent gradual
diffusion of paclitaxel all over the cell is observed suggesting a complementary picture of
the pharmaceutical action of this drug based on rapid binding of free tubulin to crystallized
paclitaxel.VC 2013 American Institute of Physics. [http://dx.doi.org/10.1063/1.4794871]
Paclitaxel has been used extensively as an antitumor,1
anti-leukemic drug,2 and recently its benefiting effect in pre-
venting restenosis has been reported.3 Paclitaxel is also used
in cell biology research, as a pro-apoptotic drug. In a classi-
cal view paclitaxel (C47H51NO14, molecular weight 835Da)
is categorized as a microtubule-stabilizing agent.4 It binds
directly to the inner surface of microtubules, inducing a con-
formational change that increases its affinity for neighbor
tubulin. Paclitaxel strongly reduces the free energy of poly-
merization, increases sharply microtubules mass, and their
dynamic elongation is almost completely suppressed.5,6 A
recent study showed that the paclitaxel molecule binds also
to a second site, forming a groove between a-tubulin and b-
tubulin monomers.7 In this case the molecule is partially
exposed to the solution and may serve as a bridge, connect-
ing other paclitaxel molecules and leading to the formation
of paclitaxel spherulites that are frequently mistaken for
microtubule asters.7 Moreover, at commonly used concentra-
tions (1–20 lM) paclitaxel binds tubulin subunits rather than
microtubule generating asters and bundles that can masquer-
ade as stabilized microtubules.8 This unexpected property of
the drug would lead to reinterpretation of many microtubule-
based studies. It is then worthwhile to carefully investigate
internalization of paclitaxel in living cells in order to study
the validity of this theory. The observation of paclitaxel
forming asters of high diameters7 would confirm it, and also
spreading of paclitaxel all over the cell will challenge the
classical theory.
Common methods to study distribution and mapping of
drugs in fixed and live cells include use of fluorescent label-
ing.9 Although fluorescence techniques are well established,
certain difficulties are encountered, such as low contrast and
photo-bleaching; also, introduction of fluorescent labels may
potentially alter the biochemical properties of the molecule of
interest. Alternatively confocal Raman microscopy appears as
a unique tool for chemical cell imaging and protein conforma-
tion imaging.10–14 Raman spectra of cells are very complex
because they contain the fingerprints of all molecules present.
Raman spectral maps of individual cells15–18 and localization
of intracellular nanoparticles12,19,20 have been achieved. The
main advantages of confocal Raman microscopy include high
spatial resolution and a unique compositional sensitivity
intrinsic to spectroscopic methods.9 Tracing drugs within cells
no longer need any label since the drug’s Raman signature
enables their detection in the cell. Moreover, cell’s Raman
spectra can be also recorded reflecting the cell’s biochemical
composition in the laser spot volume. Since the spectral con-
trast between cellular components is relatively small, images
need to be treated using multivariate methods of analysis.21
By direct Raman microscopy, Raman images of MDA-435
breast cancer cells treated with highly concentrated (350lM)
paclitaxel have been acquired at a single selected Raman peak
(1000 cm1) with 0.54lm resolution.22 In this work we
provide data on paclitaxel distribution at close to clinical
concentrations (10lM) in live cancerous MCF-7 (Michigan
Cancer Foundation-7) cells based on a set of Raman spectral
lines of paclitaxel, using a higher resolution (300 300
 800 nm) confocal Raman spectroscopy. For better image
contrast we complete the experimental work with cluster anal-
ysis and correlation map calculations.
The MCF-7 cells, derived from a metastatic breast cancer
patient in 1970, were the first cancer cell line capable of living
longer than few months and now became a standard model in
cancer research laboratories.23 MCF-7 were grown in 75 cm2
culture flasks (VWR, Strasbourg, France) in a media contain-
ing 7ml DMEM (Dulbecco’s modified eagle’s medium),
(Thermo Fisher, Strasbourg, France), 20% FBS, and 1%
antibiotics (Streptomycin 100lg/ml penicillin, 100 U/ml) at
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37 C and 5% CO2. Cells were cultivated onto polished CaF2
substrates (Crystran Ltd, Dorset, UK). CaF2 reveals a Raman
peak at 320 cm1 and hence has no interference with major
cell’s Raman lines. After 24 h the cells adhered on CaF2 sub-
strate. Paclitaxel (Taxol, Teva Pharmaceutical Ind., Tel Aviv,
Israel) was then added to the culture medium: cells were incu-
bated for three, six, and nine hours in DMEM containing
paclitaxel and then washed three times with PBS (Phosphate
Buffer Saline) (Invitrogen, Grand Island, USA), enabling the
time tracing of paclitaxel in the cell. The CaF2 substrates with
adhered cells were transferred into Petri dishes containing
5ml PBS. PBS was selected because it does not create fluo-
rescence as DMEM. Clinical amount of paclitaxel in each
treatment injection, given by pharmaceutical manufacturer, is
175mg/m2. By using Mosteller formula for body surface area
and then Hume-Weyer formula for total body water, we are
able to calculate the equivalent amount of paclitaxel for cell
culture medium that in our experiments is 9.7lg/ml.
Tracking of time-dependent distribution of paclitaxel in cells
was followed by Raman microscopy. Raman spectra were
collected using a Witec confocal Raman microscope system
alpha 300R (Witec Inc., ULM, Germany). Excitation in
the confocal Raman microscopy is assured by a frequency
doubled Nd:YAG laser (Newport, Evry, France) at a wave-
length of 532 nm, 50mW power at laser output, single longi-
tudinal mode. The light is carried to microscope by a
multimode fiber (diameter of 125lm). The incident laser
beam is focused onto the sample through a 60 NIKON
water immersion objective having a numerical aperture of
1.0, and a working distance of 2.8mm (Tokyo, Japan). The
acquisition time of a single spectrum was 0.5 s. 150 points per
line and 150 lines per image were recorded, leading to a total
of 22500 spectra for one image, each spectrum corresponding
to a spatial unit defined as a voxel. We present in Fig. 1(a) the
bright field image of MCF7 living cells in PBS solution. The
low contrast in the bright field image is due to the absence
of staining. (c) Refers to the total integrated Raman intensities
of the CH-stretching mode, in specific spectrum regions
(2800–3000 cm1) corresponding to the CH band. The Witec
Project software provides a Sum Filter. By choosing the spe-
cific spectra region in Sum Filter, we could extract an image
based on integrated Raman intensities of a specific region.
Bright yellow hues indicate highest intensities and dark hues
the lowest integrated intensities of the chosen region, respec-
tively. In (c), bright yellow hues corresponding to high inten-
sities of CH stretching band, belong inside the cell and dark
hues the lowest integrated intensities of CH stretching band
belong to PBS with no CH band. (b) Shows the results of
K-mean cluster analysis (KMCA) of the data set for six clus-
ters. K-means clustering partitions data into k mutually exclu-
sive clusters. K-means treats each observation in the data set
as an object having a location in space. It finds a partition in
which objects within each cluster are as close to each other as
possible, and as far from objects in other clusters as possible.
K-means uses an iterative algorithm that minimizes the sum
of distances from each object to its cluster centroid, over all
clusters. This algorithm moves objects between clusters until
the sum cannot be decreased further. The result is a set of
clusters that are as compact and well-separated as possible
X
SJi  mk:
The distance between each spectral vectors SJi and cluster
centroids mk has to be minimized for each group of clusters.
21
KMCA was realized using the Witec Project Plus (Ulm,
Germany) software. K-mean clustering was performed in
the 500–1800 cm1 and 2600–3200 cm1 spectral domains.
These regions were chosen because they contain sufficient
spectral information of cell components and provide the best
clustering results. Figure 1(c) depicts a Raman image con-
structed via KMCA revealing clusters matching nucleus
(blue), nucleolus (pink), cytoplasm (orange), membrane (light
green), endoplasmic reticulum (dark green), as well as differ-
ent components in cytoplasm.
In Fig. 2 we present a typical Raman spectrum of a cell
(a), the Raman spectrum of the paclitaxel solution prepared
from paclitaxel (Teva Ind, Tel Aviv, Israel) (b) and the
Raman spectrum of paclitaxel (Sigma-Aldrich, France 95%
FIG. 1. (a) Bright-field microscopic image of MCF-7 cell in buffer solution,
60 objective. (b) Integrated Raman intensities in the 2800–3000 cm1
region of the cell shown in (a) collected at a dwell time of 0.5 s/point and a
point spacing of around 300 nm. Bright yellow hues indicate the highest and
dark hues the lowest integrated C-H stretching intensities, respectively.
(c) Raman image of various cell components obtained via KMCA clusters
based on data shown in (b) and corresponding to the Raman spectra region
of 500–1800 cm1 and 2600–3200 cm1.
FIG. 2. Predominant bands in the Raman spectra of (a) cytoplasm and endo-
plasmic reticulum; (b) clinical paclitaxel solution from Teva Ind.; (c) pure
paclitaxel powder from Sigma-Aldrich.
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purity) in powder (c), respectively. The Raman vibrations
obtained for the paclitaxel used in our research are very simi-
lar to the spectra previously reported for functional deriva-
tives of the paclitaxel.6 Comparison between Figs. 2(a) and
2(b) shows that most of Raman peaks appearing in the spec-
tra of cells overlap with the vibrational peaks of the pacli-
taxel. Moreover, the previously used peak by Ling et al.22 at
1002 cm1 which is due to sp3 hybridized carbon-carbon
(C-C) vibration in the paclitaxel occurs also in the cell’s
spectra. Therefore in our work the peak at 1740 cm1 (the
C¼O stretching band marked in the red spectrum of
Fig. 2(b)) was used to monitor paclitaxel in cells.
Cells cultured for 24 h in DMEM and then incubated for
3 h in a solution of DMEM containing paclitaxel (9.7lM)
were rinsed with PBS and transferred under the confocal
Raman microscope. Fig. 3(a) shows the results of KMCA anal-
ysis of MCF-7 cell’s images, when the cells were incubated
with paclitaxel for three hours. The images reveal seven clus-
ters, corresponding to different parts of the cell and the back-
ground signal of the PBS buffer and the CaF2 substrate. The
spectral contrast between cellular components is relatively
small as they are very similar in terms of Raman vibrations.
But precisely it is possible to reveal very small differences
between the various parts of the cell.15,21 The average spectra
of nucleus (orange) nucleolus (dark green), cytoplasm (pink),
membrane (brown), endoplasmic reticulum (light blue), and
paclitaxel (red) calculated by KMCA are plotted in Fig. 3(b).
The peak positions, band shapes, and intensities are very alike,
considering that cell basic components are quite similar; how-
ever, there are noticeable differences in specific spectral
regions. For example the symmetric uracil or thymine ring
breathing mode with a frequency at 785 cm1 is observed quite
strongly for the nuclear and cytoplasmic regions but much less
for the mitochondria.9 The number of spectra contributing to
the average spectra of each cluster is in order of thousands.
Consequently the observed signal to noise ratio for an average
spectrum is very good. Fig. 3(b) evidences that the (red) spec-
trum of paclitaxel is very similar to the cell components’ spec-
tra; therefore, the drug was monitored after clustering an
average spectra containing the specific peak of paclitaxel at
1740 cm1 (C¼O stretching in Fig. 2). As this band has a very
low intensity compared to the whole spectra, clustering has to
be performed several times. Finally by comparing the cluster
of average spectrum with the drug reference spectrum, we are
able to identify the cluster corresponding to paclitaxel.
As the paclitaxel (red cluster in Fig. 3(a)) cluster con-
tains several single spectra, each of them was compared to
the reference paclitaxel spectrum (Fig. 2) and showed a very
good match. Beside the K-mean cluster, a spectral correla-
tion matrix was calculated,21 to find the most similar spec-
trum to the reference spectrum of paclitaxel. To quantify
the similarity, as a “distance,” the Pearson’s correlation
FIG. 3. (a) Seven cluster Raman map of MCF7
cells. (b) Average spectra corresponding to clus-
ters in (a) (same colors as in (a)): the average
spectra of nucleus (orange) nucleolus (dark
green), cytoplasm (pink), membrane (brown),
endoplasmic reticulum (light blue), PBS buffer
(light green) and paclitaxel (red). (c) Correlation
map of the same image. (d) The correlation coef-
ficient between the whole spectra and the one of
paclitaxel taken as a reference (black spectrum).
The best correlation is obtained for the paclitaxel
in cell (red spectrum); the region with no correla-
tion to paclitaxel is due to the PBS buffer (blue
spectrum).
FIG. 4. Raman images of MCF7 cells incubated
in paclitaxel. Integrated Raman intensities in the
2800–3000 cm1 region of the cell, marking
paclitaxel as red spot. (a) 3 h; (b) 6 h; (c) 9 h
incubation of cells in culture medium containing
paclitaxel.
113701-3 Salehi et al. Appl. Phys. Lett. 102, 113701 (2013)
 This article is copyrighted as indicated in the abstract. Reuse of AIP content is subject to the terms at: http://scitation.aip.org/termsconditions. Downloaded to IP:
160.114.60.72 On: Mon, 18 Nov 2013 14:50:54
coefficient was calculated for each pair of spectra, given by
the following formula:
r ¼
XN
i¼1 xi  Xð Þ yi  Yð Þð ÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXN
i¼1ðxi  XÞ
2
XN
i¼1ðyi  YÞ
2
q ;
where N is the number of points within the spectrum, xi and
yi are the individual points, and X and Y are the mean value
of each spectrum. The value of r can vary between 1 and 1;
thus, it can be expressed as a percentage ranging from
100%, no correlation, to 100%, the perfect match. From
these values, a pseudo color map can be constructed, reflect-
ing the quantified similarities. All calculations were per-
formed with a homemade code written in MatLab (Math
Works, Inc, Massachusetts, USA). The correlation coeffi-
cient map of the same image is depicted in Fig. 3(c).
Paclitaxel spectrum as a reference was compared to all spec-
tra of the same image, resulting in a correlation map shown
in Fig. 3(c). The numbers of 100 and 100 in the color bar
stand for the best and worst correlation (expressed in %)
between all cell spectra and paclitaxel spectrum. We observe
that the lowest correlation (14.5%, turquoise color) corre-
sponds to PBS and the best correlation indicated by the red
color corresponds to paclitaxel. In the correlation coefficient
map the same position of paclitaxel as in the cluster analysis
was obtained, confirming our KMCA results. In Fig. 3(d) we
present the (black) spectrum of paclitaxel and the corre-
sponding, best correlation (47.2%, red spectrum) as well as
the worst correlation (14.5%, blue spectrum) obtained for
the phosphate buffer region, respectively. Our analyses dem-
onstrate clearly the capability of KMCA to distinguish pacli-
taxel based on the molecule’s Raman vibrations. Relying on
the results of KMCA the next step was tracing paclitaxel ver-
sus different incubation times to monitor uptake pathways of
the drug in cells. Figure 4 presents the Raman images of
MCF-7 cells after different incubation times in paclitaxel
solution. The paclitaxel cluster (red) obtained by KMCA
was superposed on the Raman image of the cell (integrated
Raman intensities in the 2800–3000 cm1 region, using sum
filter) using Image J software (National Institutes of Health,
Maryland, USA). Fig. 4(a) shows cells after three hours of
incubation in paclitaxel: the drug had passed the cell mem-
brane and entered the cytoplasm.
The same protocol was used to obtain Figs. 4(b) and 4(c),
presenting MCF7 cells incubated six and nine hours in pacli-
taxel containing culture medium, respectively. Images clearly
reveal an increase of paclitaxel uptake by cells versus time
and its distribution in numerous parts of the cells. The drug is
gradually diffusing into the cytoplasm, but it does not enter
cell nucleus. The ratio of the number of pixels belonging to
paclitaxel cluster over the number of pixels corresponding to
the cell was calculated and represented by bars in Fig. 5. This
ratio representing the amount of paclitaxel in the cells
increases with the incubation time of cells with the drug. The
number of cells containing paclitaxel is also increasing with
time (Table I). After three hours of culture with paclitaxel
85% of cells show an uptake of the drug, while after nine
hours 90% were involved. Para-nitrophenyl phosphate (pNPP)
and Trypan Blue viability tests show that after incubation for
three and six hours in paclitaxel, 80% of cells were alive and
at nine hours incubation, 60% survived. In other words inter-
pretation of Raman images has to be done considering that for
three and six hours of culture with paclitaxel, 80% of cells
were alive, thus still on the CaF2 substrate among these 85%
and 80% uptake paclitaxel, respectively. After nine hours of
culture with paclitaxel only 60% of cells were still adhered on
the CaF2 substrate and among them 90% uptake paclitaxel.
Intracellular pharmacokinetics of Paclitaxel was devel-
oped taking into account saturable drug binding to extracellu-
lar proteins, saturable and nonsaturable drug binding to
intracellular components, time- and concentration-dependent
drug depletion from culture medium, and cell density-
dependent drug accumulation.24 Differential equations were
solved to calculate the paclitaxel concentration in MCF7 cells
(Python Software Foundation, Netherland). Initial cell number,
initial drug concentration, average cell volume, and medium
volume taken from our measurement, Michaelis–Menten con-
stants, and some physical constants for calculation from Kuh
et al.24 were introduced in differential equations to obtain the
time dependent concentration simulation of our measurement.
dCtotal;c
dt
¼
Aþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
A2 þ 4:Kd;m:Ctotal;m
q
2

Bþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
B2 þ 4: ð1þ NSBÞKd;c:Ctotal;c
q
2:ð1þ NSBÞ
2
4
3
5: CLf
Vone cell
 kcell number:Ctotal; c;
FIG. 5. Paclitaxel pixel over cell pixel at different incubation times in pacli-
taxel. (*) Student t test approves significance of data.
TABLE I. Paclitaxel uptake after 3, 6, and 9 h of incubation.
Timea (h) % cellsb
3 85
6 80
9 90
aTime of paclitaxel in culture medium.
bPercentage of cells positive for paclitaxel/total number of live cells.
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dCtotal;m
dt
¼
Aþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
A2 þ 4:Kd;m:Ctotal;m
q
2

Bþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
B2 þ 4: ð1þ NSBÞKd;c:Ctotal;c
q
2:ð1þ NSBÞ
2
4
3
5:CLf :ICN:e
kcell number:t
Vm
;
A ¼ Kd;m þ Bmax;m  Ctotal;m;
B ¼ ð1þ NSBÞ:Kd;c þ Bmax;c:ð1þ kBmax;c:tÞ  Ctotal;c;
Vonecell ¼ 4p3 :L:W:H¼ 2.1ll/106 cell, average cell volume,
Lmaximum,Wminimum diameter of cell, H height of cell,
Vm (5ml): volume of the medium,
Bmax;m ð3:94 lMÞ , Kd;mð781 nMÞ: Michaelis–Menten con-
stants of drug binding to cellular components,
Bmax;cð 59:2lMÞ, Kd;cð4:93nMÞ: Michaelis–Menten con-
stants of drug binding to protein in medium,
NSB (0.148): Proportionality constant for nonsaturable
binding site in cells
ICN (106): initial cell number,
CLf ð3:34 103 ll =h =cellÞ: Clearance of free drug by
passive diffusion,
kcell number ð0:0053h1Þ: Rate constant for change in cell
number,
kBmax;c ð 31:3 103 h1Þ: Rate constant for increase of B
max, c (maximal saturable binding site),
Ctotal;c, Ctotal;m: Total drug concentration in cell and medium.
The mean cell volume is calculated by converting
the pixels to micrometers for the ellipsoid MCF7 cell.
Experimentally the minimum amount of paclitaxel detectable
by Raman microscopy was determined as 100lM. Therefore
for 3 h of incubation, using the mean of the pixel of paclitaxel
divided by cell pixel (Fig. 5) and multiplying the percentage of
cell with paclitaxel, gives the concentration of drug inside the
cell. For 3 h incubation time the Raman measurement gives the
concentration of 0.51lM, for 6 h and 9 h paclitaxel concentra-
tions were 1.84lM and 3.78lM, respectively. The numerical
solution for the coupled differential equations results in a drug
concentration for 3 h of 0.953lM and of 1.911lM and
2.876lM for 6 h and 9 h, respectively. The good agreement
between the calculated and observed paclitaxel concentration
within the cells shows that Raman microscopy can be used to
study intracellular pharmacokinetics of paclitaxel.
The main achievements and conclusion of our work can be
summarized as follows. Confocal Raman microscopy measure-
ments combined with cluster analysis and correlation map cal-
culations allowed monitoring the internalization of paclitaxel at
clinically used concentrations in live MCF7 cancerous cells.
Our high resolution images demonstrate that paclitaxel diffuses
all over in the cell cytoplasm. The mean diameter of the pacli-
taxel area measured after cluster analysis for cell incubated 6 h
with paclitaxel is 1.776 0.27lm. This size is compatible with
the size of the in-vitro paclitaxel aster-like structure in which
the majority of the material is located in the center. An evalua-
tion calculated from Fig 1 in Foss et al. (2008) gives 70% of
the paclitaxel situated in the central area of 1.3lm of diameter.
In a previous work using the 1002 cm1 Raman band the
studied cells have round shape, in contrast with adhered cell
shape of the MCF 7 cells.22 This might lead to different inter-
pretation due to different cell physiology and difficulty to
identify the different cytoplasmic compartments. We have
not observed drug localization around bundles of stabilized
microtubules that would have been expected according the clas-
sical picture of paclitaxel’s pharmaceutical action.25
Furthermore the validity of all the classical works based on fluo-
rescent labeling is challenged by the theory of paclitaxel crystal
formation. This theory is based on in-vitro observation of aster-
like paclitaxel crystal and tubulin binding on crystal allowing
confusion with microtubule.7,8 Paclitaxel crystals inducing
sequestration of free tubulin could induce cytotoxicity in non-
dividing cells leading to cell death rather than by paclitaxel’s
direct interference with mitotic spindle.12 Furthermore, pixel
analysis enabled to trace the dynamics of the drug’s diffusion
process in cells versus time and also a relative quantification of
the uptaken amount of paclitaxel. Our work settles bases
towards the reinterpretation of chemotherapeutical drug’s action
on cancerous cells susceptible to promote elaboration of phar-
maceutical methods to increase efficiency of anticancer drugs.
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